A detailed history of Zeke Capital Advisors, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Zeke Capital Advisors, LLC holds 780 shares of REGN stock, worth $557,848. This represents 0.04% of its overall portfolio holdings.

Number of Shares
780
Previous 488 59.84%
Holding current value
$557,848
Previous $337,000 66.77%
% of portfolio
0.04%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$705.89 - $766.39 $206,119 - $223,785
292 Added 59.84%
780 $562,000
Q3 2022

Nov 14, 2022

BUY
$573.97 - $724.32 $5,739 - $7,243
10 Added 2.09%
488 $337,000
Q2 2022

Aug 09, 2022

BUY
$548.35 - $738.84 $10,418 - $14,037
19 Added 4.14%
478 $283,000
Q1 2022

May 13, 2022

BUY
$595.12 - $698.43 $273,160 - $320,579
459 New
459 $320,000
Q1 2020

Apr 24, 2020

SELL
$336.18 - $494.43 $424,595 - $624,465
-1,263 Closed
0 $0
Q4 2019

Jan 17, 2020

BUY
$274.13 - $376.51 $9,320 - $12,801
34 Added 2.77%
1,263 $474,000
Q3 2019

Oct 18, 2019

BUY
$273.46 - $318.39 $1,640 - $1,910
6 Added 0.49%
1,229 $341,000
Q2 2019

Jul 24, 2019

SELL
$299.6 - $414.82 $16,478 - $22,815
-55 Reduced 4.3%
1,223 $383,000
Q1 2019

Apr 29, 2019

SELL
$372.08 - $439.57 $309,570 - $365,722
-832 Reduced 39.43%
1,278 $525,000
Q4 2018

Feb 11, 2019

SELL
$335.82 - $403.04 $696,154 - $835,501
-2,073 Reduced 49.56%
2,110 $788,000
Q3 2018

Nov 08, 2018

BUY
$351.14 - $408.51 $3,862 - $4,493
11 Added 0.26%
4,183 $1.69 Million
Q2 2018

Jul 24, 2018

BUY
$284.6 - $344.99 $1.19 Million - $1.44 Million
4,172 New
4,172 $1.44 Million
Q4 2017

Feb 14, 2018

SELL
$358.63 - $469.95 $286,545 - $375,490
-799 Closed
0 $0
Q3 2017

Nov 09, 2017

BUY
$431.38 - $504.0 $344,672 - $402,696
799
799 $357,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $76.7B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Zeke Capital Advisors, LLC Portfolio

Follow Zeke Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zeke Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Zeke Capital Advisors, LLC with notifications on news.